Andere Sprachen TriSalus Life Sciences, Inc.

Aktien

TLSI

US89680M1018

TLSI

Schlusskurs Nasdaq Andere Börsenplätze 00:00:00 15.05.2024			% 5 Tage	% 1. Jan.
9,39 ^USD	-7,49 %		-4,48 %	+11,12 %

15.05.	TriSalus Life Sciences, Inc. meldet Ergebnis für das erste Quartal bis zum 31. März 2024	CI
15.05.	TriSalus Life Sciences, Inc. gibt eine Umsatzprognose für das Gesamtjahr 2024 ab	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

TriSalus Life Sciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	15.05.
Earnings Flash (TLSI) TRISALUS LIFE SCIENCES Posts Q1 Revenue $6.5M, vs. Street Est of $5.9M	15.05.
TriSalus Reports Q1 2024 Financial Results and Business Update	15.05.
TriSalus Life Sciences, Inc. Provides Sales Guidance for the Full Year of 2024	15.05.
TriSalus Life Sciences Appoints Liselotte Hyveled to its Board of Directors	07.05.
TriSalus Life Sciences, Inc. Appoints Liselotte Hyveled to Its Board of Directors	07.05.
TriSalus Life Sciences to Host First Quarter 2024 Financial Results Conference Call	06.05.
TriSalus Life Sciences Obtains $50 Million Debt Facility	01.05.
TriSalus Life Sciences Secures up to $50 million of Debt Financing with OrbiMed to Support TriNav® Infusion System Growth Initiatives	30.04.
TriSalus Life Sciences, Inc. announced that it expects to receive $50 million in funding from OrbiMed Advisors LLC	30.04.
TriSalus Reports Q4 and Full Year 2023 Financial Results and Business Update	01.04.
TriSalus Life Sciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	01.04.
TriSalus Life Sciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	01.04.
Earnings Flash (TLSI) TRISALUS LIFE SCIENCES Reports Q4 Revenue $5.7M	01.04.
TriSalus Life Sciences Technology Featured in Two Presentations at the Society of Interventional Radiology Annual Scientific Meeting	26.03.
TriSalus Life Sciences Announces Oral Presentations at the Upcoming 2024 Society of Interventional Radiology (SIR) Annual Scientific Meeting	21.03.
TriSalus Life Sciences Announces Q4 Conference Call and Preliminary and Unaudited Q4 and Full Year 2023 Financial Results	11.03.
TriSalus Life Sciences, Inc. Provides Preliminary Unaudited Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2023; Provides Revenue Guidance for the Full Year 2024	11.03.
TriSalus Life Sciences Receives Approval from the World Health Organization and the American Medical Association’s Adopted Name Council for “Nelitolimod” as the Nonproprietary Drug Name for SD-101	07.03.
TriSalus Life Sciences Announces Real-World Data Demonstrating the Ability of TriNav® to Successfully Treat Patients with Higher Disease Burden and to Improve Delivery of Therapeutics to Liver Tumors	29.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen TriSalus Life Sciences, Inc.

Aktien

TLSI

US89680M1018

TLSI

Andere Sprachen

Filter